Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Imaging correlates of axonal swelling in chronic multiple sclerosis brains.

Fisher E, Chang A, Fox RJ, Tkach JA, Svarovsky T, Nakamura K, Rudick RA, Trapp BD.

Ann Neurol. 2007 Sep;62(3):219-28.

PMID:
17427920
2.

Gray matter involvement in multiple sclerosis.

Pirko I, Lucchinetti CF, Sriram S, Bakshi R.

Neurology. 2007 Feb 27;68(9):634-42. Review. Erratum in: Neurology. 2008 Dec 9;71(24):2021.

PMID:
17325269
3.

A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study.

Gauthier SA, Glanz BI, Mandel M, Weiner HL.

Autoimmun Rev. 2006 Oct;5(8):532-6. Epub 2006 Mar 22. Review.

PMID:
17027888
4.

MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability.

Li DK, Held U, Petkau J, Daumer M, Barkhof F, Fazekas F, Frank JA, Kappos L, Miller DH, Simon JH, Wolinsky JS, Filippi M; Sylvia Lawry Centre for MS Research..

Neurology. 2006 May 9;66(9):1384-9.

PMID:
16682671
5.

The measurement and clinical relevance of brain atrophy in multiple sclerosis.

Bermel RA, Bakshi R.

Lancet Neurol. 2006 Feb;5(2):158-70. Review.

PMID:
16426992
6.

Spinal cord imaging in multiple sclerosis.

Tench CR, Morgan PS, Jaspan T, Auer DP, Constantinescu CS.

J Neuroimaging. 2005;15(4 Suppl):94S-102S. Review.

PMID:
16385022
7.

Clinical-magnetic resonance imaging correlations in multiple sclerosis.

Zivadinov R, Leist TP.

J Neuroimaging. 2005;15(4 Suppl):10S-21S. Review.

PMID:
16385015
8.

Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS.

Ann Neurol. 2005 Dec;58(6):840-6. Review.

PMID:
16283615
9.

Pilot study to examine the effect of antibiotic therapy on MRI outcomes in RRMS.

Sriram S, Yao SY, Stratton C, Moses H, Narayana PA, Wolinsky JS.

J Neurol Sci. 2005 Jul 15;234(1-2):87-91.

PMID:
15935383
10.

Measurement of whole-brain atrophy in multiple sclerosis.

Pelletier D, Garrison K, Henry R.

J Neuroimaging. 2004 Jul;14(3 Suppl):11S-19S. Review.

PMID:
15228755
11.

Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis.

Miller DH, Thompson AJ, Filippi M.

J Neurol. 2003 Dec;250(12):1407-19. Review.

PMID:
14673572
12.

Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years.

Bagnato F, Jeffries N, Richert ND, Stone RD, Ohayon JM, McFarland HF, Frank JA.

Brain. 2003 Aug;126(Pt 8):1782-9. Epub 2003 Jun 23.

PMID:
12821527
13.

A semiautomated measure of whole-brain atrophy in multiple sclerosis.

Bermel RA, Sharma J, Tjoa CW, Puli SR, Bakshi R.

J Neurol Sci. 2003 Apr 15;208(1-2):57-65.

PMID:
12639726
14.

Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy.

Wei X, Warfield SK, Zou KH, Wu Y, Li X, Guimond A, Mugler JP 3rd, Benson RR, Wolfson L, Weiner HL, Guttmann CR.

J Magn Reson Imaging. 2002 Feb;15(2):203-9.

PMID:
11836778
15.

Correlates of MS disability assessed in vivo using aggregates of MR quantities.

Mainero C, De Stefano N, Iannucci G, Sormani MP, Guidi L, Federico A, Bartolozzi ML, Comi G, Filippi M.

Neurology. 2001 May 22;56(10):1331-4.

PMID:
11376183
16.

United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.

Wolinsky JS, Narayana PA, Johnson KP; Multiple Sclerosis Study Group and the MRI Analysis Center..

Mult Scler. 2001 Feb;7(1):33-41.

PMID:
11321192
17.

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW.

N Engl J Med. 2000 Sep 28;343(13):898-904.

18.

Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators.

Wolinsky JS, Narayana PA, Noseworthy JH, Lublin FD, Whitaker JN, Linde A, Gj├Ârstrup P, Sullivan HC.

Neurology. 2000 May 9;54(9):1734-41.

PMID:
10802777
19.

A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium.

Jacobs LD, Wende KE, Brownscheidle CM, Apatoff B, Coyle PK, Goodman A, Gottesman MH, Granger CV, Greenberg SJ, Herbert J, Krupp L, Lava NS, Mihai C, Miller AE, Perel A, Smith CR, Snyder DH.

Mult Scler. 1999 Oct;5(5):369-76.

PMID:
10516782
20.

Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E.

Brain. 1999 May;122 ( Pt 5):871-82.

PMID:
10355672

Supplemental Content

Support Center